Cytosorbents Corporation logo
Cytosorbents Corporation CTSO
$ 0.68 1.32%

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Cytosorbents Corporation Financial Statements 2011-2026 | CTSO

Annual Financial Statements Cytosorbents Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

54.4 M 44.7 M 157 M 161 M 407 M 160 M 227 M 210 M 141 M 95.6 M 115 M 66.1 M 20.8 M 23.9 M

Shares

54.4 M 44.7 M 43.6 M 43.4 M 38.8 M 32.3 M 30.7 M 27.6 M 25.4 M 24.9 M 14.4 M 9.44 M 7.93 M 6.41 M

Historical Prices

1 1 3.61 3.72 10.5 4.94 7.49 7.6 5.55 3.84 8.02 7 2.58 3.75

Net Income

-20.7 M -29.2 M -32.8 M -24.6 M -7.84 M -19.3 M -17.2 M -8.46 M -11.9 M -8.13 M -9.32 M -4.68 M -3.66 M -5.48 M

Revenue

35.6 M 31.1 M 9.39 M 10.8 M 12 M 24.9 M 22.5 M 15.2 M 9.53 M 4.79 M 4.12 M 2.42 M 1.34 M 36.1 K

Cost of Revenue

10.5 M 9.13 M 14 M 11 M 11.1 M 7.36 M 7.49 M 5.52 M 3.95 M - - - - -

Gross Profit

25.1 M 22 M 5.76 M 7.66 M 9.43 M 17.6 M 15 M 9.63 M 5.57 M 2.58 M 1.99 M 511 K 1.02 M 24.3 K

Operating Income

-16.8 M -31.9 M -6.36 M -9.56 M -2.63 M -19 M -15.6 M -9.84 M -11.5 M -9.3 M -6.89 M -4.71 M -3.49 M -4.44 M

EBITDA

-15.2 M -30.5 M -5.47 M -8.83 M -1.97 M -18.4 M -15.2 M -9.62 M -11.3 M -9.19 M -7.21 M -4.65 M -3.44 M -4.4 M

Operating Expenses

41.9 M 53.9 M 52.3 M 54.9 M 40.3 M 36.6 M 30.6 M 19.5 M 17.1 M 11.9 M 9.27 M 5.22 M 4.51 M 4.46 M

General and Administrative Expenses

35 M 38.3 M 34.3 M 35.8 M 28.5 M 24.5 M 22.9 M 15.4 M 12.3 M 8.01 M 6.84 M 3.49 M 1.98 M 1.57 M

All numbers in USD currency

Quarterly Income Statement Cytosorbents Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

62.8 M 62.6 M 60.7 M 54.8 M 54.5 M 54.3 M 54.4 M 54.2 M 44.4 M 44 M 43.7 M 43.6 M 43.6 M 43.6 M 43.5 M 43.5 M 43.4 M 43.3 M 43.2 M 43.2 M 41.6 M 36.5 M 34 M 32.6 M 32.4 M 32.3 M 31.9 M 31.8 M 31.3 M 30.3 M 29.4 M 29 M 28.2 M 28 M 25.5 M 25.5 M 25.4 M 25.4 M 25.4 M 25.4 M 25 M 24.8 M 24.4 M 23.3 M 12.5 M 12 M 10.6 M 10.1 M 243 M 232 M 223 M 215 M 204 M 194 M 181 M 178 M 168 M 159 M 178 M

Net Income

-3.17 M 1.95 M -1.48 M - -2.77 M -4.29 M -6.09 M - -9.19 M -6.15 M -7.33 M - -12.2 M -10.9 M -8.97 M -9.31 M -6.41 M -4.68 M -4.17 M -678 K -840 K -2.87 M -3.45 M -3.95 M -6.89 M -3.55 M -4.88 M -5.4 M -3 M -5.82 M -2.98 M -3.15 M -2.05 M -1.73 M -1.52 M -4.91 M -2.19 M -3.01 M -1.84 M -2.53 M -2.85 M 1.43 M -4.72 M -10.5 M -1.5 M -1.85 M -975 K - -965 K -1.41 M -1.63 M - -652 K -1.05 M -1.43 M - -1.73 M -1.34 M -1.21 M

Revenue

9.48 M 9.62 M 8.73 M - 8.61 M 8.84 M 8.99 M - 8.81 M 9.42 M 9.45 M - 8.11 M 8.5 M 8.69 M 10.8 M 9.76 M 12 M 10.6 M 12 M 10.5 M 9.79 M 8.71 M 7.43 M 6.1 M 6.23 M 5.19 M 6.08 M 5.74 M 5.76 M 4.92 M 4.65 M 3.82 M 3.57 M 3.11 M 3.08 M 2.41 M 2.22 M 1.81 M 1.76 M 1.34 M 964 K 723 K 874 K 1.16 M 1.02 M 1.06 M - 881 K 291 K 371 K - 605 K 83 K 50.2 K - - - -

Cost of Revenue

2.82 M 2.8 M 2.52 M - 3.36 M 2.34 M 2.12 M - 3.2 M 3.4 M 3.99 M - 4.49 M 3.55 M 2.28 M - 2.46 M 2.71 M 2.75 M - 2.89 M 3.25 M 2.38 M - 1.7 M 1.83 M 1.74 M - 2.05 M 1.79 M 1.57 M - 1.52 M 1.48 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

6.67 M 6.81 M 6.21 M - 5.26 M 6.5 M 6.87 M - 5.61 M 6.02 M 5.46 M - 3.62 M 4.94 M 6.41 M 7.66 M 7.3 M 9.31 M 7.85 M 9.43 M 7.66 M 6.55 M 6.32 M 5.34 M 4.4 M 4.4 M 3.45 M 4 M 3.69 M 3.97 M 3.36 M 3.38 M 2.31 M 2.08 M 1.86 M 1.79 M 1.45 M 1.35 M 991 K 957 K 705 K 499 K 419 K 544 K 686 K 359 K 400 K - 260 K 91.9 K 118 K - 463 K 73 K -3.61 K - - - -

Operating Income

-2.86 M -3.62 M -3.89 M - -4.83 M -3.57 M -4.66 M - -7.35 M -6.56 M -7.89 M - -9.02 M -8.36 M -7.79 M -9.56 M -5.41 M -4.92 M -2.85 M -2.63 M -1.96 M -3.3 M -2.48 M -5.43 M -5.63 M -3.63 M -4.29 M -5.59 M -2.71 M -4.19 M -3.1 M -3.81 M -2.15 M -2.33 M -1.56 M -4.57 M -2.14 M -2.69 M -2.09 M -2.21 M -2.15 M -2.23 M -2.71 M -2.89 M -1.48 M -1.36 M -1.15 M - -880 K -1.41 M -1.42 M - -601 K -1.01 M -1.07 M - -1.23 M -1.11 M -1.13 M

EBITDA

-2.56 M - -3.52 M - -4.53 M - -4.26 M - - - -7.63 M - -8.36 M -8.36 M -7.57 M -9.56 M -4.89 M -4.92 M -2.7 M -2.63 M -1.46 M -2.96 M -2.3 M -5.43 M -5.21 M -3.35 M -4.15 M -5.59 M -2.45 M -4.07 M -3.04 M -3.81 M -1.99 M -2.23 M -1.49 M -4.57 M -2.03 M -2.62 M -2.06 M -2.21 M -2.07 M -2.18 M -2.69 M -2.89 M -1.41 M -1.32 M -1.13 M - -832 K -1.38 M -1.41 M - -569 K -988 K -1.06 M - -1.18 M -1.08 M -1.12 M

Operating Expenses

9.53 M 10.4 M 10.1 M - 10.1 M 10.1 M 11.5 M - 13 M 12.6 M 13.3 M - 12.6 M 13.3 M 14.2 M - 12.7 M 14.2 M 10.7 M - 9.62 M 9.84 M 8.8 M - 10 M 8.03 M 7.74 M - 6.4 M 8.16 M 6.46 M - 4.46 M 4.42 M 3.42 M - 3.59 M 4.04 M 3.08 M - 2.86 M 2.73 M 2.68 M - 2.17 M 1.72 M 1.55 M - 1.14 M 1.5 M 1.54 M - 1.06 M 1.08 M 1.06 M - 1.23 M 1.11 M 1.13 M

General and Administrative Expenses

8.61 M 9.17 M 8.43 M - 8.26 M 8.55 M 9.28 M - 8.1 M 7.72 M 8.46 M - 8.74 M 8.44 M 9.16 M - 7.78 M 9.82 M 7.71 M - 7.28 M 6.59 M 6.32 M - 6.11 M 4.51 M 4.76 M - 4.04 M 6.12 M 4.32 M - 3.57 M 3.51 M 2.67 M - 2.14 M 2.63 M 1.97 M - 1.7 M 1.63 M 1.52 M - 1.24 M 1.21 M 1.08 M - 688 K 601 K 613 K - 360 K 293 K 269 K - 352 K 192 K 270 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Cytosorbents Corporation CTSO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Cytosorbents Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.57 0.1 % $ 687 M israelIsrael
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 22.65 -0.15 % $ 3.24 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
AxoGen AxoGen
AXGN
$ 33.63 0.78 % $ 1.49 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.5 1.16 % $ 121 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.66 -3.56 % $ 136 M franceFrance
Electromed Electromed
ELMD
$ 28.9 -0.41 % $ 244 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 323.76 1.47 % $ 9.13 B usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 97.6 -0.79 % $ 144 B usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 43.07 -2.56 % $ 1.33 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 54.12 3.12 % $ 8.06 K usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 125.84 -0.27 % $ 219 B usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.47 1.47 % $ 1.15 B israelIsrael
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.16 -2.94 % $ 18.7 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
LENSAR LENSAR
LNSR
$ 11.6 -0.6 % $ 134 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 15.77 -2.65 % $ 601 M curacaoCuracao
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Align Technology Align Technology
ALGN
$ 172.23 0.97 % $ 12.9 B usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.89 -0.47 % $ 91.5 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 98.81 -1.19 % $ 1.25 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.06 -1.63 % $ 407 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 18.56 0.02 % $ 122 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 3.78 -1.32 % $ 14.1 M usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 4.82 8.8 % $ 78.6 M usaUSA
Globus Medical Globus Medical
GMED
$ 94.0 -0.66 % $ 12.8 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 13.69 -1.23 % $ 1.05 B usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 369.46 0.61 % $ 141 B usaUSA